| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
| S87900-2mg | 98% | ￥90.00 | 货期：2-3天 | - | - | - |
|
| S87900-5mg | 98% | ￥150.00 | 货期：2-3天 | - | - | - |
|
| S87900-10mg | 98% | ￥260.00 | 货期：2-3天 | - | - | - |
|
| S87900-25mg | 98% | ￥430.00 | 货期：2-3天 | - | - | - |
|
| S87900-50mg | 98% | ￥670.00 | 货期：2-3天 | - | - | - |
|
| S87900-100mg | 98% | ￥950.00 | 货期：2-3天 | - | - | - |
|
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation
| 产品描述： | SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | p38α MAPK:3.2 nM (IC50);p38β MAPK:122 nM (IC50);p38MAPK | ||||||||||||||||||||
| 参考文献： | 1. Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京